Table 1:
Summary of main characteristics of study participants
| HPR (n=554) |
GALA II (n=2181) |
GACRS (n=1019) |
SCAALA (n=256) |
|
|---|---|---|---|---|
| Age in years (mean ± SD) | 10.0±2.7 | 12.7±3.3 | 9.2±1.9 | 7.2±1.9 |
| Male sex (n, %) | 300 (54.2) | 1196 (54.8) | 598 (58.7) | 139 (54.3) |
| Asthma exacerbation (n, %) | 236 (42.6) | 1283 (58.8) | 851 (83.5) | 139 (54.3) |
| Inhaled steroid use (n, %) | 187 (33.8) | 996 (45.7) | 521 (51.1) | Not available |
| FEV1 % pred#(mean ± SD) | 86.8±16.0 | 90.6±16.3 | 99.1±17.3 | Not available |
| FEV1/FVC % pred#(mean ± SD) | 91.8±9.8 | 96.3± 8.8 | 94.5±8.7 | Not available |
| Study sites | Hartford (CT) and San Juan (Puerto Rico) | Chicago (IL), Bronx (NY), Houston (TX), San Francisco (CA) and Puerto Rico | Costa Rica | Salvador (Bahia), Brazil |
| Genotyping platform | Illumina 2.5M | Affymetrix Axiom® LAT1 | Illumina Human Omni Express-12v1_A | Illumina Human Omni 2.5-8v1 |
HPR: Hartford-Puerto Rico study. GALA II: Genetics of Asthma in Latino Americans II study. GACRS: Genetics of Asthma in Costa Rica Study. SCAALA: Social Changes, Asthma and Allergy in Latin America study; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity.
#
: for comparability, all percent predicted values across the three studies were calculated using reference values for Mexican American youth [45].